Acasti Pharma Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Prashant Kohli
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3009 boulevard de la Concorde East Laval QC Canada H7E 2B5
- IPO Date
- Feb 7, 2012
- CIK
- 0001444192
- Website
- acastipharma.com
- Similar Companies
- Business
- Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) is a late-stage biopharmaceutical company focused on developing and commercializing novel drug delivery technologies and drug candidates addressing rare and orphan diseases. Founded in 2002 and headquartered in Princeton, New Jersey, with operations in Laval, Quebec, Canada, and R&D facilities in North Brunswick, New Jersey, the company targets unmet medical needs in neurology and pain management through proprietary formulations that enable faster onset of action, enhanced efficacy, reduced side effects, and improved patient compliance. Its lead product candidates include GTX-104, an intravenous nanoparticle formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH); GTX-102, an oral mucosal spray of betamethasone for ataxia-telangiectasia (A-T), a pediatric neurodegenerative disorder; and GTX-101, a topical bio-adhesive spray of bupivacaine for postherpetic neuralgia (PHN); all three assets have received U.S. FDA Orphan Drug Designation, providing seven years of market exclusivity upon approval, supported by over 40 granted and pending patents. Recent developments encompass the full enrollment of the Phase 3 STRIVE-ON trial for GTX-104 ahead of schedule, with topline data expected in early 2025 and a New Drug Application submission to the FDA planned for the first half of 2025; a corporate name change from Acasti Pharma Inc. to Grace Therapeutics, Inc. in October 2024, accompanied by a ticker symbol shift to GRCE on Nasdaq effective October 28, 2024; re-domiciliation to Delaware as a U.S. corporation; a $7.5 million private placement equity financing in September 2023 led by ADAR1 Partners, LP; divestment of legacy assets including the prior omega-3 focus; pipeline prioritization; and management team restructuring to support an agile biopharma model.
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
Acasti Pharma to Attend BIO International Convention 2024
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)
Acasti Announces $7.5 Million Private Placement Equity Financing
Acasti to Participate in the H.C. Wainwright Global Investment Conference
Acasti Announces First Quarter 2024 Financial Results and Business Highlights
Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting